CTIX is nothing like PYMX. CTIX has plenty of money to get through clinical trials that should lead to a partnership deal of some kind. The PYMX management bet everything on the wrong drug, dropped the Brilacidin trial (because they used a massive dose instead of the much smaller dose CTIX is using), got a toxic financing deal, and went under. It must be a bitter pill for the shareholders who lost money on it, to know that with good management THEY would be the ones who owned a piece of Brilacidin -- on the verge of so many clinical trial results that look incredibly promising.

Leo Ehrlich knows better than to take on toxic financing. The shorts picked the wrong company to try to bankrupt. And hopefully, they are going to pay hugely for that mistake in the near future.

That goes for former bashers turned pumpers.